+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Pain associated with Painful Diabetic Neuropathy - Market Insight, Competitive Landscape and Market Forecast, 2026

  • ID: 5314054
  • Report
  • April 2021
  • Region: Global
  • 206 pages
  • DelveInsight

FEATURED COMPANIES

  • Abbott
  • Daiichi Sankyo
  • Erchonia Corporation
  • Grünenthal
  • Nevro Corp.
  • Ono pharmaceuticals
This ‘Chronic Pain associated with Painful Diabetic Neuropathy- Market Insight, Competitive Landscape and Market Forecast, 2026' report delivers an in-depth understanding of Chronic Pain associated with Painful Diabetic Neuropathy and the historical and forecasted Chronic Pain associated with Painful Diabetic Neuropathy market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Chronic Pain associated with Painful Diabetic Neuropathy market report provides an overview of Chronic Pain associated with Painful Diabetic Neuropathy, its cause, signs and symptoms, pathophysiology, diagnosis and currently available therapies. Additionally, this report covers the overview, various treatment practices, and Chronic Pain associated with Painful Diabetic Neuropathy forecasted epidemiology from 2018 to 2026, segmented by the seven major markets. The report also covers the market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Chronic Pain associated with Painful Diabetic Neuropathy Understanding

Chronic Pain associated with Painful Diabetic Neuropathy Overview

Neuropathy is the most usual complication that occurs due to diabetes, affecting up to about 50% of the patients. Painful diabetic neuropathy (PDN) occurs in approximately 25% of patients with diabetes mellitus who are treated in the office setting and significantly affects quality of life. It typically causes burning pain, paresthesias, and numbness in a stocking-glove pattern that progresses proximally from the feet and hands. These patients get treated in office settings, and it affects their quality of life. It also occurs in 30% of the patients suffering from diabetes mellitus, and they are often hospitalized. According to a definition given by IASP (International Association for the Study of Pain), painful diabetic neuropathy may be defined as a pain arising as a direct consequence of abnormalities in the somatosensory system in people with diabetes.

Based on current practice guidelines, these medications, with gabapentin and amitriptyline, should be considered for the initial treatment. Second-line therapy includes opioid-like medications (tramadol and tapentadol), venlafaxine, desvenlafaxine, and topical agents (lidocaine patches and capsaicin cream). Opioids and selective serotonin reuptake inhibitors are optional third-line medications.

Geography Covered
  • The US
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2018-2026

List of Companies:
  • Grünenthal
  • Daiichi Sankyo
  • Janssen Pharmaceuticals/Grunethal
  • Pfizer
  • Eli Lilly and Shionogi
  • Ono pharmaceuticals
  • Fremslife S.r.l.
  • Helixmith
  • Aptinyx
  • Regenacy Pharmaceuticals
  • Novaremed
  • Nevro Corp.
  • Erchonia Corporation
  • Regenesis Biomedical, Inc.
  • Abbott
  • ZyGood LLC
Chronic Pain associated with Painful Diabetic Neuropathy- Competitive Analysis

This segment of the report provides a brief competitive analysis of Chronic Pain associated with Painful Diabetic Neuropathy to help understand the competition in the market. It gives a comparative understanding of the products based on parameters such as type of regulatory approval.

Chronic Pain associated with Painful Diabetic Neuropathy: Market Segmentation

By Pharmacotherapy
  • Antidepressants (Amitriptyline, Nortriptyline, Despiramine, Duloxetine, Venlafaxine etc.)
  • Anticonvulsants (Carbamazepine, Gabapentin, Pregablin, Valproate sodium)
  • Opioids (Morphine sulphate, oxycodone CR)
  • Opioid like analgesics (Dextromethorphan, Tramadol, other than Nucynta ER)
  • Opioid like analgesics (Nucynta ER)
  • Topical medications (Capsaicin cream, lidocaine patch)
  • QUTENZA (8% capsaicin)
  • Tarlige (JP)
  • VM202
  • NYX-2925
  • WST-057 (4% pirenzepine)
  • Ricolinostat
  • NRD.E1
  • Cebranopadol
  • GRC 17356
By Medical Devices
  • Frequency Modulated Neural Stimulation (FREMS) (Aptiva)
  • TENS (Transcutaneous Electrical Nerve Stimulation, such as Quell, Techcare Tens Unit etc.)
  • Senza Omnia
Chronic Pain associated with Painful Diabetic Neuropathy: Eligible Patient Population

This segment of the report provides an analysis of the eligible patient pool that incorporate Chronic Pain associated with Painful Diabetic Neuropathy for their treatment, across 7MM during the study period (2018 and 2030).

Chronic Pain associated with Painful Diabetic Neuropathy: Eligible Patient Population in the United States

This segment of the report provides an analysis of the eligible patient pool that incorporate Chronic Pain associated with Painful Diabetic Neuropathy for their treatment, across the United States during the study period (2018 and 2030).

Chronic Pain associated with Painful Diabetic Neuropathy: Market Analysis

This segment illustrates the market of Chronic Pain associated with Painful Diabetic Neuropathy across 7MM and how the market is expected to rise in the study period (2018 to 2026), at a CAGR of XX%.

Chronic Pain associated with Painful Diabetic Neuropathy: Market Drivers and Barriers

The report provides insights into the market driving factors and the barriers shaping the Chronic Pain associated with Painful Diabetic Neuropathy market.

Market Drivers:
  • Rising prevalence and incidence of diabetes
  • Increasing complexities related to diabetes that involve nerve damage and blindness.
  • Increasing geriatric population globally
Market Barriers:
  • High cost associated with the treatment of Chronic Pain associated with Painful Diabetic Neuropathy
  • Availability of alternate forms of therapies comprising traditional medicines and physiotherapy
KOL- Views

To keep up with the market trends, we take KOLs and SME's opinion working in Chronic Pain associated with Painful Diabetic Neuropathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Pain associated with Painful Diabetic Neuropathy market trend. This will support the clients in making informed business decisions by identifying the overall scenario of the market and the unmet needs.

Scope of the Report
  • The report covers the descriptive overview of Chronic Pain associated with Painful Diabetic Neuropathy explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
  • Comprehensive insight has been provided into the epidemiology of the Chronic Pain associated with Painful Diabetic Neuropathy and its treatment in the 7MM
  • Additionally, a complete account of both the current and emerging treatment for Chronic Pain associated with Painful Diabetic Neuropathy is provided, along with the assessment of new therapies, which is likely to have an impact on the current market landscape.
  • A detailed review of Chronic Pain associated with Painful Diabetic Neuropathy market; historical and forecasted market size is included in the report, covering devices outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Pain associated with Painful Diabetic Neuropathy market.
Report Highlights
  • The report covers descriptive overview of Chronic Pain associated with Painful Diabetic Neuropathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
  • The report provides an insight into the patient population eligible for Chronic Pain associated with Painful Diabetic Neuropathy in the 7MM, covering the US, EU5 (Germany, Spain, France, Italy, UK) & Japan.
  • The report is a comprehensive account of marketed devices present in the Chronic Pain associated with Painful Diabetic Neuropathy market.
  • The report also reviews the detailed global historical and forecasted Chronic Pain associated with Painful Diabetic Neuropathy market including assessing the outreach in 7MM.
  • The report helps in developing business strategies by understanding trends shaping and driving the global Chronic Pain associated with Painful Diabetic Neuropathy market.
Chronic Pain associated with Painful Diabetic Neuropathy Report Key Strengths
  • 6 Years Forecast
  • 7MM Coverage
  • Competitive Landscape
  • Patient pool
  • Market Size
Chronic Pain associated with Painful Diabetic Neuropathy Report Assessment
  • Marketed Product profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
  • Market Forecast
  • KOL'S views
  • PEST Analysis
Key Questions Answered

Market Insights:
  • What was the Chronic Pain associated with Painful Diabetic Neuropathy market share (%) distribution in 2018 and how it will look like in 2026?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Pain associated with Painful Diabetic Neuropathy market size during the forecast period (2018-2026)?
  • At what CAGR, the Chronic Pain associated with Painful Diabetic Neuropathy market is expected to grow in 7MM during the forecast period (2018-2026)?
  • What will be the Chronic Pain associated with Painful Diabetic Neuropathy market outlook across the 7MM during the forecast period (2018-2026)?
  • What will be the Chronic Pain associated with Painful Diabetic Neuropathy market growth till 2026 and what will be the resultant market size in the year 2026?
  • How will the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
Competitive Landscape:
  • What are the current devices available in the Chronic Pain associated with Painful Diabetic Neuropathy market?
  • What is the Chronic Pain associated with Painful Diabetic Neuropathy available in the market, their product description, regulatory milestones, product development activities, research and development activities etc.?
  • How many key players are developing Chronic Pain associated with Painful Diabetic Neuropathy?
  • What are the key collaborations (Industry-Industry), Mergers and acquisitions, licensing activities related to the Chronic Pain associated with Painful Diabetic Neuropathy?
  • What are the key designations that have been granted for the current Chronic Pain associated with Painful Diabetic Neuropathy?
  • What are the 7MM historical and forecasted market of Chronic Pain associated with Painful Diabetic Neuropathy?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Daiichi Sankyo
  • Erchonia Corporation
  • Grünenthal
  • Nevro Corp.
  • Ono pharmaceuticals
1 KEY INSIGHTS

2 REPORT INTRODUCTION

3 CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY MARKET OVERVIEW AT A GLANCE
3.1 PHARMACOTHERAPY MARKET SHARE (%) DISTRIBUTION OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY IN 2018
3.2 PHARMACOTHERAPY MARKET SHARE (%) DISTRIBUTION OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY IN 2026
3.3 MEDICAL DEVICE MARKET SHARE (%) DISTRIBUTION OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY IN 2018
3.4 MEDICAL DEVICE MARKET SHARE (%) DISTRIBUTION OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY IN 2026
EXECUTIVE SUMMARY OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY

4 DISEASE BACKGROUND AND OVERVIEW
4.1 INTRODUCTION
4.2 PATHOPHYSIOLOGY
4.3 SIGNS AND SYMPTOMS
4.4 DIAGNOSIS
4.4.1 Recent developments in early diagnosis of PDN with POPDNs
4.4.2 Differential Diagnosis
4.5 TREATMENT AND MANAGEMENT
4.6 MEDICAL DEVICE TECHNOLOGIES IN CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY

5 PATIENT JOURNEY

6 CASE REPORTS

7 EPIDEMIOLOGY AND PATIENT POPULATION
7.1 KEY FINDINGS
7.2 7MM TOTAL DIAGNOSED PREVALENT PATIENT POPULATION OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY
7.3 EPIDEMIOLOGY OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY
7.4 THE UNITED STATES
7.4.1 Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in the United States
7.4.2 Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in the United States
7.5 EU5
7.5.1 Germany
7.5.1.1 Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Germany
7.5.1.2 Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Germany
7.5.2 France
7.5.2.1 Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in France
7.5.2.2 Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in France
7.5.3 Spain
7.5.3.1 Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Spain
7.5.3.2 Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Spain
7.5.4 Italy
7.5.4.1 Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Italy
7.5.4.2 Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Italy
7.5.5 United Kingdom
7.5.5.1 Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom
7.5.5.2 Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom
7.6 JAPAN
7.6.1 Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Japan
7.6.2 Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Japan

8 MARKETED PRODUCTS- PHARMACOTHERAPY
8.1 KEY CROSS COMPETITION
8.2 QUTENZA: GRÜNENTHAL
8.2.1 Product Description
8.2.2 Mechanism of action:
8.2.3 Regulatory Milestones
8.2.4 Other developmental activities
8.2.5 Safety and Efficacy of Qutenza
8.2.6 Side effects of Qutenza
8.2.7 Product Profile
8.3 TARLIGE: DAIICHI SANKYO
8.3.1 Product Description
8.3.2 Mechanism of action
8.3.3 Regulatory Milestones
8.3.4 Safety and Efficacy of Tarlige
8.3.5 Side effects of Tarlige
8.3.6 Product Profile
8.4 NUCYNTA® ER (TAPENTADOL): JANSSEN PHARMACEUTICALS/GRUNETHAL
8.4.1 Product Description
8.4.2 Mechanism of action
8.4.3 Regulatory Milestones
8.4.4 Other developmental activities
8.4.5 Safety and Efficacy of Nucynta ER
8.4.6 Side effects of Nucynta ER
8.4.7 Product Profile

9 MARKETED PRODUCTS- MEDICAL DEVICES
9.1 KEY CROSS COMPETITION
9.2 FREQUENCY RHYTHMIC ELECTRICAL MODULATION SYSTEM (FREMS)
9.2.1 Product Description
9.2.2 Regulatory Milestones
9.2.3 Research and Development
9.3 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) THERAPY
9.3.1 Technology Description

10 EMERGING PHARMACOTHERAPIES
10.1 KEY CROSS COMPETITION
10.2 ENGENSIS (VM202): HELIXMITH
10.2.1 Drug Description
10.2.2 Regulatory Milestones
10.2.3 Clinical Development
10.2.4 Clinical Trials Information
10.2.5 Safety and Efficacy
10.2.6 Product Profile
10.3 NYX-2925: APTINYX
10.3.1 Drug Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Clinical Trials Information
10.3.5 Safety and Efficacy
10.3.6 Product Profile
10.4 WST-057: WINSANTOR
10.4.1 Drug Description
10.4.2 Regulatory Milestones
10.4.3 Clinical Development
10.4.4 Clinical Trials Information
10.4.5 Product Profile
10.5 RICOLINOSTAT: REGENACY PHARMACEUTICALS
10.5.1 Drug Description
10.5.2 Regulatory Milestones
10.5.3 Clinical Development
10.5.4 Clinical Trials Information
10.5.5 Safety and Efficacy
10.5.6 Product Profile
10.6 CEBRANOPADOL: GRÜNENTHAL
10.6.1 Drug Description
10.6.2 Regulatory Milestones
10.6.3 Clinical Development
10.6.4 Clinical Trials Information
10.6.5 Safety and Efficacy
10.6.6 Product Profile
10.7 ISC 17536: ICHNOS SCIENCE
10.7.1 Drug Description
10.7.2 Regulatory Milestones
10.7.3 Clinical Development
10.7.4 Clinical Trials Information
10.7.5 Safety and Efficacy
10.7.6 Product Profile
10.8 NRD135S.E1: NOVAREMED
10.8.1 Drug Description
10.8.2 Clinical Development
10.8.3 Clinical Trials Information
10.8.4 Safety and Efficacy
10.8.5 Product Profile
10.9 OTHER POTENTIAL THERAPIES
10.9.1 MEDI7352: AstraZeneca
10.9.1.1 Drug Description
10.9.1.2 Clinical Development
10.9.1.3 Clinical Trials Information
10.9.1.4 Product Profile
10.9.2 Trazodone/Gabapentin: Angelini
10.9.2.1 Drug Description
10.9.2.2 Clinical Development
10.9.2.3 Clinical Trials Information
10.9.2.4 Product Profile

11 EMERGING MEDICAL DEVICES
11.1 KEY CROSS COMPETITION
11.2 SCS HF10 TECHNOLOGY
11.2.1 Technology Description
11.2.2 Regulatory Milestones
11.2.3 Research and Development
11.3 LOW-LEVEL LASER TECHNOLOGY
11.3.1 Technology Description
11.3.2 Regulatory Milestones
11.3.3 Clinical Development
11.4 PULSED ELECTROMAGNETIC FIELD (PEMF) THERAPY
11.4.1 Technology Description
11.4.2 Regulatory Milestones
11.4.3 Clinical Development
11.5 DORSAL ROOT GANGLION (DRG) STIMULATION
11.5.1 Technology Description
11.5.2 Regulatory Milestones
11.5.3 Clinical Development
11.6 TRANSCUTANEOUS MAGNETIC STIMULATION (TCMS)
11.6.1 Technology Description
11.6.2 Clinical Development

12 CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY: 7 MAJOR MARKET ANALYSIS
12.1 KEY FINDINGS- PHARMACOTHERAPY
12.2 KEY FINDINGS- MEDICAL DEVICES
12.3 TOTAL MARKET SIZE OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY IN 7MM
12.4 PHARMACOTHERAPY MARKET SIZE OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY IN 7MM
12.5 MARKET SIZE OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY BY PHARMACOTHERAPIES
12.6 MEDICAL DEVICE MARKET SIZE OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY IN 7MM
12.7 MARKET SIZE OF CHRONIC PAIN ASSOCIATED WITH PAINFUL DIABETIC NEUROPATHY BY MEDICAL DEVICE
12.8 MARKET OUTLOOK
12.9 UNITED STATES MARKET SIZE
12.9.1 Total Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the United States
12.9.2 Total Pharmacotherapy Market size of Chronic Pain associated with Painful Diabetic Neuropathy in United States
12.9.3 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Pharmacotherapies in the United States
12.9.4 Total Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the United States
12.9.5 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in the United States
12.1 EU-5 MARKET SIZE
12.10.1 Germany
12.10.1.1 Total Market size of Chronic Pain associated with Painful Diabetic Neuropathy in Germany
12.10.1.2 Total Pharmacotherapy Market size of Chronic Pain associated with Painful Diabetic Neuropathy in Germany
12.10.1.3 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Pharmacotherapies in Germany
12.10.1.4 Total Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Germany
12.10.1.5 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in Germany
12.10.2 France
12.10.2.1 Total Market size of Chronic Pain associated with Painful Diabetic Neuropathy in France
12.10.2.2 Total Pharmacotherapy Market size of Chronic Pain associated with Painful Diabetic Neuropathy in France
12.10.2.3 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Pharmacotherapies in France
12.10.2.4 Total Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in France
12.10.2.5 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in France
12.10.3 Italy
12.10.3.1 Total Market size of Chronic Pain associated with Painful Diabetic Neuropathy in Italy
12.10.3.2 Total Pharmacotherapy Market size of Chronic Pain associated with Painful Diabetic Neuropathy in Italy
12.10.3.3 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Pharmacotherapies in Italy
12.10.3.4 Total Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Italy
12.10.3.5 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in Italy
12.10.4 Spain
12.10.4.1 Total Market size of Chronic Pain associated with Painful Diabetic Neuropathy in Spain
12.10.4.2 Total Pharmacotherapy Market size of Chronic Pain associated with Painful Diabetic Neuropathy in Spain
12.10.4.3 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Pharmacotherapies in Spain
12.10.4.4 Total Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Spain
12.10.4.5 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in Spain
12.10.5 United Kingdom
12.10.5.1 Total Market size of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom
12.10.5.2 Total Pharmacotherapy Market size of Chronic Pain associated with Painful Diabetic Neuropathy in United Kingdom
12.10.5.3 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Pharmacotherapies in the United Kingdom
12.10.5.4 Total Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom
12.10.5.5 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in the United Kingdom
12.11 JAPAN
12.11.1 Total Market size of Chronic Pain associated with Painful Diabetic Neuropathy in Japan
12.11.2 Total Pharmacotherapy Market size of Chronic Pain associated with Painful Diabetic Neuropathy in Japan
12.11.3 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Pharmacotherapies in Japan
12.11.4 Total Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Japan
12.11.5 Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in Japan

13 KOL VIEWS

14 MARKET DRIVERS

15 MARKET BARRIERS

16 SWOT ANALYSIS

17 UNMET NEEDS

18 APPENDIX
18.1 BIBLIOGRAPHY
18.2 REPORT METHODOLOGY

19 Publisher Capabilities

20 DISCLAIMER

21 About the Publisher

List of Tables
Table 1: Summary of Chronic Pain associated with Painful Diabetic Neuropathy, Market, Epidemiology, and Key Events (2018-2030)
Table 2: The Toronto Diabetic Neuropathy Diagnostic definition
Table 3: A summary of the common tests used to assess neuropathy
Table 4: Screening and Diagnosis Recommendations by the American Diabetes Association
Table 5: Guidelines recommend the frequency and mode of assessment
Table 6: Clinical utility of devices used for the diagnosis of diabetic peripheral neuropathy
Table 7: Differential diagnosis of diabetic neuropathies
Table 8: Diagnosed Prevalent Patient Population of Chronic Pain associated with Painful Diabetic Neuropathy in 7MM (2018-2030)
Table 9: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in the United States (2018-2030)
Table 10: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in the United States (2018-2030)
Table 11: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Germany (2018-2030)
Table 12: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Germany (2018-2030)
Table 13: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in France (2018-2030)
Table 14: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in France (2018-2030)
Table 15: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Spain (2018-2030)
Table 16: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Spain (2018-2030)
Table 17: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Italy (2018-2030)
Table 18: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Italy (2018-2030)
Table 19: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom (2018-2030)
Table 20: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom (2018-2030)
Table 21: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Japan (2018-2030)
Table 22: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Japan (2018-2030)
Table 23: Key cross of Marketed Drugs
Table 24: Key cross of emerging drugs- I
Table 25: Key cross of the emerging drugs -II
Table 26: VM202, Clinical Trial Description, 2020
Table 27: NYX-2925, Clinical Trial Description, 2020
Table 28: WST-057, Clinical Trial Description, 2020
Table 29: NYX-2925, Clinical Trial Description, 2020
Table 30: Cebranopadol, Clinical Trial Description, 2020
Table 31: ISC 17536, Clinical Trial Description, 2020
Table 32: NRD135S.E1, Clinical Trial Description, 2020
Table 33: MEDI7352, Clinical Trial Description, 2020
Table 34: Trazodone/Gabapentin, Clinical Trial Description, 2020

List of Figures
Figure 1: Pathophysiology of Chronic Pain associated with Painful Diabetic Neuropathy
Figure 2: Signs and Symptoms of Chronic Pain associated with Painful Diabetic Neuropathy
Figure 3: Treatment of Chronic Pain associated with Painful Diabetic Neuropathy
Figure 4: Treatment of Chronic Pain associated with Painful Diabetic Neuropathy
Figure 5: Diagnosed Prevalent Patient Population of Chronic Pain associated with Painful Diabetic Neuropathy in 7MM (2018-2030)
Figure 6: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in the United States (2018-2030)
Figure 7: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in the United States (2018-2030)
Figure 8: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Germany (2018-2030)
Figure 9: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Germany (2018-2030)
Figure 10: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in France (2018-2030)
Figure 11: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in France (2018-2030)
Figure 12: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Spain (2018-2030)
Figure 13: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Spain (2018-2030)
Figure 14: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy
Figure 15: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Italy (2018-2030)
Figure 16: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom (2018-2030)
Figure 17: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom (2018-2030)
Figure 18: Diagnosed Prevalent Cases of Chronic Pain associated with Painful Diabetic Neuropathy in Japan (2018-2030)
Figure 19: Treatable Population of Chronic Pain associated with Painful Diabetic Neuropathy in Japan (2018-2030)
Figure 20: APTIVA 4 and SPEEDER WH Fremslife, Technology
Figure 21: Transcutaneous Electrical Nerve Stimulation (TENS) therapy
Figure 22: Nevro's proprietary HF10 therapy, Senza
Figure 23: Erchonia FX 635 uses low-level laser technology
Figure 24: Pulsed Electromagnetic Field (PEMF) therapy, Provant Therapy System
Figure 25: Dorsal root ganglion (DRG) stimulation therapy
Figure 26: Total Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in USD Million (2018-2026)
Figure 27: Pharmacotherapy Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in USD Million (2018-2026)
Figure 28: 7 Major Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Pharmacotherapies in USD Million (2018-2026)
Figure 29: Medical Device 7 Major Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in USD Million (2018-2026)
Figure 30: 7 Major Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in USD Million (2018-2026)
Figure 31: Total Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the United States, USD Million (2018-2026)
Figure 32: Pharmacotherapy Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the United States, USD Million (2018-2026)
Figure 33: The United States Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Therapies in USD Million (2018-2026)
Figure 34: Medical Device Market Size of Chronic Pain associated with Painful Diabetic
Figure 35: The United States Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in USD Million (2018-2026)
Figure 36: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Germany,
Figure 37: Pharmacotherapy Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the Germany, USD Million (2018-2026)
Figure 38: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Therapies in Germany, USD Million (2018-2026)
Figure 39: Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Germany, USD Million (2018-2026)
Figure 40: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in Germany, USD Million (2018-2026)
Figure 41: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the France, USD Million (2018-2026)
Figure 42: Pharmacotherapy Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the France, USD Million (2018-2026)
Figure 43: France Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Therapies in USD Million (2018-2026)
Figure 44: Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in France, USD Million (2018-2026)
Figure 45: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in France, USD Million (2018-2026)
Figure 46: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Italy, USD Million (2018-2026)
Figure 47: Pharmacotherapy Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the Italy, USD Million (2018-2026)
Figure 48: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Therapies in Italy, USD Million (2018-2026)
Figure 49: Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Italy, USD Million (2018-2026)
Figure 50: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in Italy, USD Million (2018-2026)
Figure 51: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the Spain, USD Million (2018-2026)
Figure 52: Pharmacotherapy Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the Spain, USD Million (2018-2026)
Figure 53: Spain Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Therapies in USD Million (2018-2026)
Figure 54: Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Spain, USD Million (2018-2026)
Figure 55: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in Spain, USD Million (2018-2026)
Figure 56: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom, USD Million (2018-2026)
Figure 57: Pharmacotherapy Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom, USD Million (2018-2026)
Figure 58: The United Kingdom Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Therapies in USD Million (2018-2026)
Figure 59: Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the United Kingdom, USD Million (2018-2026)
Figure 60: The United Kingdom Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in USD Million (2018-2026)
Figure 61: Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Japan, USD Million (2018-2026)
Figure 62: Pharmacotherapy Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in the Japan, USD Million (2018-2026)
Figure 63: The Japan Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Therapies in USD Million (2018-2026)
Figure 64: Medical Device Market Size of Chronic Pain associated with Painful Diabetic Neuropathy in Japan, USD Million (2018-2026)
Figure 65: The Japan Market Size of Chronic Pain associated with Painful Diabetic Neuropathy by Medical Device in USD Million (2018-2026)
Note: Product cover images may vary from those shown
  • Grünenthal
  • Daiichi Sankyo
  • Janssen Pharmaceuticals/Grunethal
  • Pfizer
  • Eli Lilly and Shionogi
  • Ono pharmaceuticals
  • Fremslife S.r.l.
  • Helixmith
  • Aptinyx
  • Regenacy Pharmaceuticals
  • Novaremed
  • Nevro Corp.
  • Erchonia Corporation
  • Regenesis Biomedical, Inc.
  • Abbott
  • ZyGood LLC
Note: Product cover images may vary from those shown
Adroll
adroll